Navigation Links
Merck Pays More Than $400 Million to Settle Federal, State Medicaid Fraud Investigation Sparked by Qui Tam Whistleblower Case Detailing Marketing Schemes for Vioxx(R), Zocor(R), Several Other Drugs
Date:2/7/2008

in a nationwide investigation by federal and state prosecutors that returned hundreds of millions of taxpayer dollars to the Medicaid program," Cohen said.

"When we realized the extent of the fraud, we took the evidence straight to the Government. Taking on Merck required close coordination and cooperation between us and the state and federal prosecutors. This taskforce approach and unrelenting commitment won a huge victory for the taxpayers." Kleiman said.

"This landmark case exposed abuses of Medicaid's Best Price nominal price exception, and strengthened the Medicaid Rebate program to reduce the states' drug costs," Yeager said.

Aside from the huge settlement, the second largest FCA civil fraud Medicaid recovery, the case marked new ground with a collaborative investigation model that saw the relator and his lawyers work closely with state and federal Government investigators to press the case. This new investigative model, Cohen said, "will become the basis for future qui tam whistleblower investigations, especially in an age of shrinking government budgets."

The FCA, initially sponsored by President Abraham Lincoln to stop military fraud during the Civil War, allows private citizens with knowledge of fraud to help the Government recover ill-gotten gains and additional civil penalties. The FCA allows the Government to collect up to three times the amount it was defrauded, in addition to civil penalties of $5,500 to $11,000 per false claim. Whistleblowers whose cases settle or are won in court usually receive rewards representing 15 to 25 percent of qui tam recoveries.

The federal investigation was conducted by the U.S. Attorney's Office for the Eastern District of Pennsylvania, under the direction of Patrick L. Meehan, U.S. Attorney, Assistant U.S. Attorney Virginia Gibson, Chief of the Civil Division, and Assistant U.S. Attorney Viveca Parker. Parker led the broad investigation, including the review of more than 400 boxes of
'/>"/>

SOURCE PRforLAW, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
2. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. ICx Technologies Works With Merck & Co., Inc. to Develop Cancer Diagnostic Technology
5. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
6. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
7. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
8. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
9. AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress
10. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
11. Merck & Co., Inc. Response to Todays New York Medicaid Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...lt University say that constant exposure to artifi...nt of premature babies' biological// clocks. The s...e researchers found that the lighting in the hospi...cal clock in the babies. Earlier research had fou...
...headache, you are probably better off eating a bow...ulatory doses of aspirin, according// to a new stu...nd that salicylic acid, the active ingredient in a...spices like cumin, turmeric and paprika, all of wh...
... Luther King Jr./Drew Medical Center explained, th...deavor to get back the accreditation along with// ... Antionette Smith Epps, chief executive of the hos...adership team that is determined to inculcate a se...
...o-school survey on teens' attitudes that covers an...ss about children’s immoral practices, one// third...here alcohol or illegal drugs were used while thei...ply that parents were aware of what was happening ...
Other Medicine News:Health News:Parents ignorant about kids' immoral practices 2
(Date:9/4/2008)...ouncements Remain on Schedule with Two Abstracts A...ata Release in November 2008, BRIDGEWATER, N.J., ...Inc., a specialty pharmaceutical company focused o...sease, today announced the appointment of,Peter L....rs., Peter Garrambone,s career includes more than...
(Date:9/3/2008)..., China, Sept. 3 /- Simcere...ufacturer and supplier of,branded generic pharmace...er biotech product Endu (also known as Endostar) i...se IV clinical study., At the request of the SFDA...urther validate the safety and therapeutic efficac...
(Date:9/3/2008)...September is National Vascular Disease Awareness M...-- Diffusion Pharmaceuticals,LLC, a clinical-stage...s,for the treatment of unmet medical needs, announ...a Phase I/II clinical trial of its lead drug,candi...signated NCT00725881,on the clinicaltrials.gov Web...
(Date:9/3/2008)...ysis showed that Multaq(R) (dronedarone) decreased...fibrillation or atrial flutter already ...RIDGEWATER, N.J., Sept. 3 /...rom the ATHENA study were presented today at,the c...ty of Cardiology,congress 2008, in Munich, Germany...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5The HealthCentral Network Adds Skin Care Site to Its Web Properties 7104 1The HealthCentral Network Adds Skin Care Site to Its Web Properties 7104 2NanoLogix Inc Files Multiple International Patent Applications for BioNanoChannel 28TM 29 and Hydrogen Bioreactor Technology 7100 1NanoLogix Inc Files Multiple International Patent Applications for BioNanoChannel 28TM 29 and Hydrogen Bioreactor Technology 7100 2MetaCure 28TM 29 Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 7096 1MetaCure 28TM 29 Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 7096 2Pneumococcal conjugate vaccines can improve the lives of HIV infected children 7092 1Pneumococcal conjugate vaccines can improve the lives of HIV infected children 7092 2
... March 27, 2007--A new study shows that as rates,o...of,cardiovascular disease (CVD) linked to diabetes...e need for increased efforts to,prevent diabetes a...ors among those with diabetes, according to the in...t Study, a program of the,National Heart, Lung, an...
...sults for the year ended 31 December 2006 , Produc...e Phase,III study International partnering process..., March 28, 2007 - CeNeS Pharmaceuticals,plc ("CeN...specialty pharmaceutical company, today announces ...mber 2006. , Operational Highlights , Clinical pip...
Other Medicine Technology:Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 2CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 3
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use.
Used for stone manipulation and removal in the urinary tract. Enhanced wire strength permits the basket to expand the ureter more readily than standard flat-wire designs. The Unidex handle facilitate
...d for stone manipulation and removal in the urinar... to retain its shape following extreme torsion. Th...ture by allowing the basket to open at the base of...ign reduces the likelihood of mucosal damage and p...
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r
Medicine Products: